Location of Repository

Estimating the cost of clinical innovation: parametric analysis of late stage pharmaceutical R&D

By G. Favato, R. W. Mills and B. Weinstein
Topics: accounting
Year: 2007
OAI identifier: oai:eprints.kingston.ac.uk:18019

Suggested articles

Preview

Citations

  1. (1991). Cost of innovation in the pharmaceutical industry, doi
  2. (1997). Drug Discovery Report, Datamonitor Healthcare Reports,
  3. (2001). Economics of Pharmaceutical Development. A review of modern valuation theories.
  4. (1997). Financial project evaluation and risk analysis in pharmaceutical development,
  5. (2000). How much does it cost to develop a new drug? Paper presented at the MSF Working Group Meeting on R&D,
  6. (2001). of Parametric Analysis (ISPA),
  7. (2001). Parametric cost analysis: From the perspective of competitive advantage,
  8. (2000). Parametric Cost Deployment. NASA Langley Research Centre,
  9. (1984). Planning Pharmaceutical clinical trials: basic statistical principles. doi
  10. (1996). Quantitative Methods in the Planning of doi
  11. (2002). Real Options evaluation in pharmaceutical R&D. A new approach to financial project evaluation.
  12. (1996). Real Options. Managerial Flexibility and Strategy in Resource Allocation. London, doi
  13. (1995). Research and Development Costs for New Drugs by Therapeutic Category, doi
  14. (1960). Statistical Cost Analysis, doi
  15. (1972). The Evaluation of Option Contracts and a Test of Market Efficiency, doi
  16. (1979). The pharmaceutical development process: estimates of current development costs and times and the effects of regulatory changes.
  17. (2001). The Pink Sheet.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.